World Marrow Donor Day is significant as it highlights the crucial role that bone marrow and stem cell donors play in saving ...

Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...

Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory ...

A potentially life-saving cancer treatment is often referred to as the original immunotherapy and it helped pave the way for ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

WILMINGTON, Del. 和 WALTHAM, Mass. - Incyte (NASDAQ:INCY) 和 Syndax Pharmaceuticals (NASDAQ:SNDX) 今天宣布，美国食品和药物管理局（FDA）最近批准了Niktimvo™（axatilimab-csfr）用于治疗体重至少40公斤的成人和儿童患者在两线系统治疗失败后的慢性移植物抗宿主病（GVHD）。这一宣布紧随 ...

PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, September 17, 2024 7.00pm CEST - BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inf ...

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as ...

In addition to the physical challenges that Tom faced during his recovery period, individuals can also experience brain fog, ...